论文部分内容阅读
[目的]探讨联合应用泮托拉唑、铝碳酸镁和莫沙比利治疗胃食管反流病(GERD)的临床疗效。[方法]将101例GERD患者随机分为A(n=36)、B(n=34)和C组(n=31),分别采用泮托拉唑+铝碳酸镁+莫沙比利、泮托拉唑+莫沙比利及铝碳酸镁+莫沙比利治疗。4及8周后评价临床症状,8周后评价内镜下有效率。[结果]治疗4周后,A、B和C组患者临床症状总改善率分别为89.9%、79.4%和61.3%,A组与B、C组相比差异有统计学意义(P﹤0.05)。治疗8周后,A、B和C组患者临床症状总改善率分别为97.2%、88.2%和71.0%,内镜下有效率分别为94.4%、86.3%和67.3%,A组临床症状总改善率和内镜下有效率与B泮托C组相比差异有统计学意义(P﹤0.05;χ2=8.6496,P﹤0.05)。[结论]泮托拉唑联合铝碳酸镁和莫沙比利治疗GERD临床疗效良好。
[Objective] To investigate the clinical efficacy of combination of pantoprazole, magnesium aluminum carbonate and mosapride in the treatment of gastroesophageal reflux disease (GERD). [Method] A total of 101 GERD patients were randomly divided into A (n = 36), B (n = 34) and C (n = 31) Tolazole + mosapride and aluminum magnesium carbonate + mosapride treatment. Clinical symptoms were evaluated 4 and 8 weeks later, and endoscopic efficiency was evaluated after 8 weeks. [Results] After 4 weeks of treatment, the total clinical symptom improvement rates of group A, B and C were 89.9%, 79.4% and 61.3% respectively. There was significant difference between group A and group B and C (P <0.05) . After 8 weeks of treatment, the total clinical symptoms in group A, B and C were 97.2%, 88.2% and 71.0% respectively, and the endoscopic effective rates were 94.4%, 86.3% and 67.3% respectively. The clinical symptoms in group A were always improved Rate and endoscopic efficiency and B Pantuo C group compared with the difference was statistically significant (P <0.05; χ2 = 8.6496, P <0.05). [Conclusion] The clinical efficacy of pantoprazole combined with hydrotalcite and mosapride in the treatment of GERD is good.